IFNγ from vaccine-boosted CAR T cells leads to antigen spreading and control of antigen-loss tumors (from Vectorportal.com).

Loss of the target antigen can limit the efficacy of chimeric antigen receptor (CAR) T-cell therapy. Ma et al. show in multiple preclinical solid tumor models that combining CAR T-cell therapy with a vaccine containing the CAR target peptide enhances tumor control by antigen spreading, preventing the emergence of antigen-loss variants. Vaccine-boosted CAR T cells undergo metabolic reprograming and have enhanced polyfunctionality, with increased IFNγ production critical for eliciting antigen spreading. Engineering CAR T cells to express IFNγ further enhances the effects of vaccine boosting in promoting antigen spreading and control of antigenically heterogenous tumors. The data highlight potential approaches for clinical translation.

Ma L, …, Irvine DJ. Cell 2023 July 5;186:3148–65.E20.

Tumor cells and DCs compete for glutamine (from Ben Mills via Wikimedia Commons).

Dendritic cells (DC) play a...

You do not currently have access to this content.